RecruitingHigh Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma

Targeted Pediatric High-Grade Glioma Therapy

Eligible age

1–39 yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.

Sponsor: Nationwide Children's Hospital

You may qualify if…

✓ 1. Age: Patients must be ≥12 months and ≤39 years of age at the time of enrollment onto this screening protocol.
✓ 2. Diagnosis: Patients with newly diagnosed HGG, including DIPG are eligible. Diagnosis must have histologic confirmation from biopsy or resection. The diagnosis of HGG must have been confirmed by pathology review at the local site. For the diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse involvement of at least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4 glioma (eg, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered diffuse midline glioma). For all other tumors, histologic grade must be WHO grade 3-4.
✓ 3. Disease Status: There are no disease status requirements for enrollment.
✓ Measurable disease is not required. Patients without measurable disease are eligible.
✓ Patients with metastatic/disseminated or multifocal disease or gliomatosis cerebri are eligible.
✓ Patients with a primary spinal tumor are eligible.
✓ Patients with secondary, radiation related HGG are eligible.
✓ 4. Prior Therapy for HGG: Surgery, radiation, and/or dexamethasone are permissible. Temozolomide concurrent with radiation is permissible. Prior administration of avastin/bevacizumab is allowed (individual treatment arms have different washout period requirements, check individual arm eligibility). No other prior anticancer therapy for HGG will be allowed.